ALXO Q2 2025 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena

ALXOALX Oncology Holdings Inc.

$112M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$27M

Net Income

-$26M

EPS (Diluted)

$-0.49

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$95M

Total Liabilities

$31M

Stockholders' Equity

$64M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$220,000	+100.0%
Operating Income	-$27M	-$42M	+35.8%
Net Income	-$26M	-$39M	+34.1%